Media hype, bad headlines & euphemisms mask trial truths. @oncology_bg calls for honesty in trials, press, and the clinic. #CommonSenseOncology is needed #ANZUP25 #EndOfLifeCare
DrAndrewWeickhardt
@WeickhardtOnc
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family
333 Following 872 Followers 995 Posts
Latest posts 5
BCG + mitomycin C vs BCG similar efficacy, fewer doses—a smart option in BCG shortage era. Combo looks better in patients with CIS and NMIBC. Early biomarker data & AI analysis may personalise NMIBC therapy #ANZUP25 #NMIBC #BladderCancer
MicroRNA-371 is outperforming traditional tumour markers in germ cell tumours. Australian trials like CLIMATE, PRESTIGE will add to data on surveillance & intensification strategies #ANZUP25
New penile cancer models (organoids & PDXs) from fresh tissue now mimic tumor biology & response. A rare cancer, but with big translational potential. A major leap from Mitch Lawrence #ANZUP25 #GUonc #PenileCancer #TranslationalOncology
🧵 Immune resistance in cancer
🛡️ T-cell exclusion? Target macrophages with PI3Kγ inhibitors (e.g. IPI-549) to open the tumor to immune attack.
Chronic interferon = double-edged sword. JAK inhibition redirects exhausted T cells back into action.
PD-1 + LAG-3 = durable IO ⚡
🛡️ T-cell exclusion? Target macrophages with PI3Kγ inhibitors (e.g. IPI-549) to open the tumor to immune attack.
Chronic interferon = double-edged sword. JAK inhibition redirects exhausted T cells back into action.
PD-1 + LAG-3 = durable IO ⚡